[3-Amino-4-(dimethylamino)thieno[2,3-b]pyridin-2-yl](phenyl)methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [3-Amino-4-(dimethylamino)thieno[2,3-b]pyridin-2-yl](phenyl)methanone
• 英文别名: [3-amino-4-(dimethylamino)thieno[2,3-b]pyridin-2-yl]-phenylmethanone
• 化学式: C₁₆H₁₅N₃OS
• 分子量: 297.381
• InChiKey: HRCCUOJXCGWDAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  87.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯-4-(二甲基氨基)烟腈 在 氢氧化钾 、 硫脲 作用下， 以 甲苯 为溶剂， 反应 4.25h， 生成 [3-Amino-4-(dimethylamino)thieno[2,3-b]pyridin-2-yl](phenyl)methanone
  参考文献：
  名称：

  4-苯基-氨基-和4-二甲氨基-3-氰基吡啶-2-硫酮和由它们得到的噻吩并[2,3-b]吡啶的合成和生物学特性

  摘要：

  在我们对此类杂环生物活性化合物的合成和研究的继续研究中，已经进行了 4-氨基吡啶的新型含硫衍生物的合成。最初，4-苯基氨基-3-氰基吡啶-2-硫酮 (I) 是通过先前开发的用于获得 4-氨基取代的吡啶-2-硫酮 [2] 的方法合成的。以氰基硫代乙酰胺为原料，与二甲基乙酰胺的二乙缩醛反应，以良好的收率得到α-氰基-/3-二甲基氨基巴豆酸硫代酰胺(III)。在乙酸介质中烯胺 (1/I) 与苯胺的转氨基作用使之前未描述的检查 (IV) 能够合成。化合物(IV)与过量二甲基甲酰胺(DMF)的缩醛的反应产生吡啶中间体(V)，将其用碱水溶液处理而不分离。开环伴随着随后的再循环，形成所需的吡啶硫酮 (I)。另一种合成吡啶-2-硫酮的方法是通过2-氯-3-氰基吡啶（Via，b）与硫脲的反应。反应在沸腾的甲苯中进行。在用碱水溶液处理中间体异硫脲盐之后，分别以63％和72％的产率获得4-苯基氨基和4-二甲氨基吡啶硫酮(I)和(VII)。在

  DOI：

  10.1007/bf00767663

文献信息

• METHODS OF TREATING MUSCULAR DYSTROPHY
  申请人：BURKIN Dean

  公开号：US20160030390A1

  公开（公告）日：2016-02-04

  Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.
• US9707210B2
  申请人：——

  公开号：US9707210B2

  公开（公告）日：2017-07-18